Technical Analysis for NCNA - NuCana plc

Grade Last Price % Change Price Change
grade C 24.5 4.17% 0.98
NCNA closed up 4.17 percent on Friday, June 22, 2018, on 24 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical NCNA trend table...

Date Alert Name Type % Chg
Jun 22 Bullish Engulfing Bullish 0.00%
Jun 22 NR7 Range Contraction 0.00%
Jun 22 Lower Bollinger Band Walk Weakness 0.00%
Jun 22 Lower Bollinger Band Touch Weakness 0.00%
Jun 22 Oversold Stochastic Weakness 0.00%
Jun 21 MACD Bearish Centerline Cross Bearish 4.17%
Jun 21 New Downtrend Bearish 4.17%
Jun 21 Lower Bollinger Band Walk Weakness 4.17%
Jun 21 Below Lower BB Weakness 4.17%
Jun 21 Down 3 Days in a Row Weakness 4.17%

Older signals for NCNA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
Is NCNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.0
52 Week Low 9.32
Average Volume 51,879
200-Day Moving Average 0.0
50-Day Moving Average 25.0071
20-Day Moving Average 26.7708
10-Day Moving Average 25.7025
Average True Range 1.9783
ADX 30.49
+DI 16.93
-DI 17.65
Chandelier Exit (Long, 3 ATRs ) 26.0651
Chandelier Exit (Short, 3 ATRs ) 28.9349
Upper Bollinger Band 30.33
Lower Bollinger Band 23.2116
Percent B (%b) 0.18
BandWidth 26.590165
MACD Line -0.2739
MACD Signal Line 0.3377
MACD Histogram -0.6116
Fundamentals Value
Market Cap 779.37 Million
Num Shares 31.8 Million
EPS -0.40
Price-to-Earnings (P/E) Ratio -61.25
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.75
Resistance 3 (R3) 26.50 25.50 26.38
Resistance 2 (R2) 25.50 24.93 25.63 26.25
Resistance 1 (R1) 25.00 24.57 25.25 25.25 26.12
Pivot Point 24.00 24.00 24.13 24.13 24.00
Support 1 (S1) 23.50 23.43 23.75 23.75 22.88
Support 2 (S2) 22.50 23.07 22.63 22.75
Support 3 (S3) 22.00 22.50 22.63
Support 4 (S4) 22.25